Recent studies showed that approximately 1/3 of RDD these patients harbor gene mutations involving the MAPK/ERK pathway, e.g., NRAS, KRAS, MAP2K1, and, rarely, BRAF, indicating a neoplastic process rather than a reactive disorder. This evidence concerns the gene MAP2K1 and sinus histiocytosis with massive lymphadenopathy.